Response of mouse skin tumors to doxorubicin is dependent on carcinogen exposure.
To investigate the role of carcinogenesis in determining the response of tumors to anticancer drugs, we have used the in vivo model of multistage carcinogenesis of the mouse skin. Mice were initiated with Harvey murine sarcoma virus or single and repeated applications of dimethylbenzanthracene (DMBA). The papillomas which developed as a result of these initiation protocols were monitored quantitatively for their response to the anticancer drug doxorubicin. A single dose of 10 mg/kg doxorubicin is relatively inefficient at reducing the frequency of papillomas arising as a result of either single or repeated applications of the chemical DMBA. However, virally initiated papillomas are sensitive to the single 10-mg/kg dose of doxorubicin and are reduced in frequency by greater than 80%. Repeat treatment with four doses of 5 mg/kg doxorubicin over a 4-week period also reveals differences in the responses of the papillomas to doxorubicin. As with the single dose of doxorubicin, papillomas initiated with multiple applications of DMBA showed only a limited response to four 5-mg/kg doses of doxorubicin. In comparison both the virally initiated and the single DMBA initiated papillomas responded to the four doses of doxorubicin and are reduced in frequency by about 80%. These data show that the response of papillomas to doxorubicin is related to the initiating event. Papillomas derived by viral initiation are most sensitive to doxorubicin while increasing the level of exposure to the chemical carcinogen DMBA increases the proportion of papillomas which do not respond to treatment with doxorubicin. There was no obvious relationship between the method of initiation or the treatment of the mice with doxorubicin and the levels of P-glycoprotein expression observed in the papillomas. All the papillomas expressed detectable levels of P-glycoprotein approaching that of the multidrug resistant cell line, CHRC5.
Keith
W N
WN
CRC Department of Medical Oncology, Beatson Institute for Cancer Research, Bearsden, Glasgow, United Kingdom.
Mee
P J
PJ
Brown
R
R
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000494:pharmacology; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000494:pharmacology; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006251:Harvey murine sarcoma virus; D008562:Membrane Glycoproteins / Q000378:metabolism; D051379:Mice; D010212:Papilloma / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002273:Carcinogens; D008562:Membrane Glycoproteins; D015127:9,10-Dimethyl-1,2-benzanthracene; D004317:Doxorubicin